Evidence map›Paper›PMID 37240028›Full record

ArticleInternational journal of molecular sciences2023

Design, Synthesis and Antitumor Activity of 1

Congyu Wang, Mei Zhu, Xuesha Long, Qin Wang, Zhenchao Wang, Guiping Ouyang

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Anticancer Activity of Ether Derivatives of Chrysin.Molecules (Basel, Switzerland) · 2025
    Review
  5. Article
  6. Design, Synthesis, andAnti-cancer agents in medicinal chemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Congyu WangCollege of Pharmacy, Guizhou University, Guiyang 550025, China.
Mei ZhuCenter for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China.
Xuesha LongCollege of Pharmacy, Guizhou University, Guiyang 550025, China.
Qin WangCollege of Pharmacy, Guizhou University, Guiyang 550025, China.
Zhenchao WangCollege of Pharmacy, Guizhou University, Guiyang 550025, China.
Guiping OuyangCollege of Pharmacy, Guizhou University, Guiyang 550025, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of indazole derivatives were designed and synthesized by molecular hybridization strategy, and these compounds were evaluated the inhibitory activities against human cancer cell lines of lung (A549), chronic myeloid leukemia (K562), prostate (PC-3), and hepatoma (Hep-G2) by methyl thiazolyl tetrazolium (MTT) colorimetric assay. Among these, compound

Indexed as

Antineoplastic AgentsNeoplasmsApoptosisCell Line, TumorCell ProliferationDrug DesignDrug Screening Assays, AntitumorHEK293 CellsHumansIndazolesMolecular StructureStructure-Activity Relationship1H-indazol-3-amineAntineoplastic AgentsIndazolesantitumor activitycell apoptosisindazole derivativesp53/MDM2 pathway

Identifiers

PMID37240028
PMCPMC10218234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.